Perrigo has signed and completed a definitive merger agreement, acquiring the remaining stake in Cobrek Pharmaceuticals, Inc., a privately-held drug development company, for approximately $45 million on a cash free and debt free basis.   In May 2008, Perrigo acquired an 18.5% minority stake in Cobrek and entered a product development collaboration focused on foam dosage form generic pharmaceutical products. The partnership has successfully yielded two commercialized foam-based products and two F...